Under the terms of the agreement, Memory Pharmaceuticals is responsible for the implementation Phase 1 clinical trials of the compound and Roche is responsible for later development and commercialization. Memory Pharmaceuticals is entitled to receive milestone payments upon the achievement of specified development, regulatory, commercialization and sales level events for R4996/MEM 63908th.. About R4996/MEM 63908R4996/MEM 63908 is a partial agonist of the nicotinic alpha – 7 receptor. Compounds which can in this receptor usefulness in improving cognitive function in diseases such as Alzheimer’s disease or schizophrenia. The compound is the second memory is developed under clinical candidates the nicotinic alpha-7 receptor agonist cooperation agreement.
The Phase 1 program for R4996/MEM 63908 included four studies: a randomized, double – blind, placebo – controlled, single ascending dose study, a food interaction study, a randomized, placebo-controlled, single dose study and a randomized, placebo-controlled, multiple-ascending dose study. Overall, the program has 130 volunteers, 66 of which awarded single doses of MEM contain 63,908 is received , 35 multiple doses of MEM 63908 and 29 received placebo.In addition, mice had been increase insulin levels and were glucose intolerant. However , the mice do not have go in to create run diabetes. ‘The realization to develop these mice, although dampened insulin signaling, showed no sign of diabetes, is welcome news , as this to assume drugs to log p110 alpha function into cancer cells possibly expects do not have the severe metabolic disorders in. ‘.. According to Dr. Vanhaesebroeck traditional mouse models function function of the PI3K protein developed to be completely removed to the p110 alpha gene. But LICR and University College London the Universities of Edinburgh and an employee Freiburg leading a single mutation in the p110 alpha gene which deactivated, but non removing, said protein.